Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale

Journal of Clinical Oncology

Volumn 30, Issue 19, 2012, Pages 2408-2417

  Brock, Penelope R ^a   Knight, Kristin R ^b   Freyer, David R ^d   Campbell, Kathleen C M ^f   Steyger, Peter S ^b   Blakley, Brian W ^g   Rassekh, Shahrad R ^h   Chang, Kay W ^e   Fligor, Brian J ⁱ   Rajput, Kaukab ^a   Sullivan, Michael ^j   Neuwelt, Edward A ^b,c  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e STANFORD UNIVERSITY   (United States)

^f SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MANITOBA   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ BOSTON CHILDREN S HOSPITAL   (United States)

^j UNIVERSITY OF OTAGO   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; CISPLATIN; DEXAMETHASONE; DNA; EBSELEN; METHIONINE; PLATINUM DERIVATIVE; RINGER SOLUTION; SODIUM THIOSULFATE;

CONSENSUS; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DNA REPAIR; DRUG MECHANISM; DRUG TRANSPORT; EAR PROTECTION; GENETICS; HUMAN; NONHUMAN; OTOTOXICITY; OTOTOXICITY SCALE; PRIORITY JOURNAL; RATING SCALE; REVIEW;

CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEARING LOSS; HUMANS; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES;

EID: 84863993868     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.1110     Document Type: Review

References (111)

1. National Cancer Institute: Cancer Drug Information: Cisplatin, May 10, 2011 update. http://www.cancer.gov/cancertopics/druginfo/cisplatin
2. Knight KR, Kraemer DF, Neuwelt EA: Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588-8596, 2005 (Pubitemid 46211500)
3. Knight KR, Kraemer DF, Winter C, et al: Early changes in auditory function as a result of platinum chemotherapy: Use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25:1190-1195, 2007 (Pubitemid 46640564)
4. Doolittle ND, Muldoon LL, Brummett RE, et al: Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493-500, 2001 (Pubitemid 32707970)
5. Neuwelt EA, Brummett RE, Doolittle ND, et al: First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther 286: 77-84, 1998 (Pubitemid 28317976)
6. Brock P, Pritchard J, Bellman S, et al: Ototoxicity of high-dose cis-platinum in children. Med Pediatr Oncol 16:368-369, 1988
7. Brock PR, Bellman SC, Yeomans EC, et al: Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 19:295-300, 1991
8. Brock PR, Yeomans EC, Bellman SC, et al: Cisplatin therapy in infants: Short and long-term morbidity. Br J Cancer Suppl 18:S36-S40, 1992
9. Walker DA, Pillow J, Waters KD, et al: Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol 17:48-52, 1989
10. Bhutani M, Pathak AK: Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100:1334, 2008; author reply 1334-1335
11. Lawenda BD, Kelly KM, Ladas EJ, et al: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100:773-783, 2008 (Pubitemid 351809666)
12. Block K, Koch A, Mead M, et al: Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 101:124-125, 2009; author reply 125-126
13. Thomas Dickey D, Muldoon LL, Kraemer DF, et al: Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 193: 25-30, 2004 (Pubitemid 38813422)
14. Dickey DT, Wu YJ, Muldoon LL, et al: Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 314: 1052-1058, 2005 (Pubitemid 41205968)
15. Laurell G, Bagger-Sjöbäck D: Dose-dependent inner ear changes after i.v. administration of cisplatin. J Otolaryngol 20:158-167, 1991
16. Hofstetter P, Ding D, Powers N, et al: Quantitative relationship of carboplatin dose to magnitude of inner and outer hair cell loss and the reduction in distortion product otoacoustic emission amplitude in chinchillas. Hear Res 112:199-215, 1997 (Pubitemid 27435996)
17. Neuwelt EA, Brummett RE, Remsen LG, et al: In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 56: 706-709, 1996 (Pubitemid 26055456)
18. Schaefer SD, Post JD, Close LG, et al: Ototoxicity of low- and moderate-dose cisplatin. Cancer 56:1934-1939, 1985 (Pubitemid 15240862)
19. Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279, 2003 (Pubitemid 37487159)
20. Neuwelt AJ, Wu YJ, Knap N, et al: Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Neoplasia 11:1003-1011, 2009
21. Park MS, De Leon M, Devarajan P: Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 13:858-865, 2002 (Pubitemid 34274081)
22. Bragado P, Armesilla A, Silva A, et al: Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 12:1733-1742, 2007 (Pubitemid 47106882)
23. García-Berrocal JR, Nevado J, Ramírez-Camach R, et al: The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear. Br J Pharmacol 152:1012-1020, 2007
24. Liu W, Staecker H, Stupak H, et al: Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. Neuroreport 9:2609-2614, 1998 (Pubitemid 28387158)
25. Cunningham LL, Cheng AG, Rubel EW: Caspase activation in hair cells of the mouse utricle exposed to neomycin. J Neurosci 22:8532-8540, 2002 (Pubitemid 35387593)
26. Matsui JI, Ogilvie JM, Warchol ME: Inhibition of caspases prevents ototoxic and ongoing hair cell death. J Neurosci 22:1218-1227, 2002 (Pubitemid 34163723)
27. Cheng AG, Cunningham LL, Rubel EW: Hair cell death in the avian basilar papilla: Characterization of the in vitro model and caspase activation. J Assoc Res Otolaryngol 4:91-105, 2003 (Pubitemid 36343580)
28. Kopke RD, Liu W, Gabaizadeh R, et al: Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 18:559-571, 1997 (Pubitemid 27428342)
29. Dehne N, Lautermann J, Petrat F, et al: Cisplatin ototoxicity: Involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 174:27-34, 2001 (Pubitemid 32635003)
30. Bánfi B, Malgrange B, Knisz J, et al: NOX3, a superoxide- generating NADPH oxidase of the inner ear. J Biol Chem 279:46065-46072, 2004 (Pubitemid 39491600)
31. Rybak LP, Whitworth CA, Mukherjea D, et al: Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226:157-167, 2007 (Pubitemid 46428033)
32. Rybak LP, Husain K, Morris C, et al: Effect of protective agents against cisplatin ototoxicity. Am J Otol 21:513-520, 2000 (Pubitemid 30432460)
33. Sergi B, Ferraresi A, Troiani D, et al: Cisplatin ototoxicity in the guinea pig: Vestibular and cochlear damage. Hear Res 182:56-64, 2003 (Pubitemid 37013284)
34. Laurell G, Ekborn A, Viberg A, et al: Effects of a single high dose of cisplatin on the melanocytes of the stria vascularis in the guinea pig. Audiol Neurootol 12:170-178, 2007 (Pubitemid 46558925)
35. Wang Q, Kachelmeier A, Steyger PS: Competitive antagonism of fluorescent gentamicin uptake in the cochlea. Hearing Res 268:250-259, 2010
36. Gormley PE, Gangji D, Wood JH, et al: Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 5:257-260, 1981 (Pubitemid 11127420)
37. Jacobs SS, Fox E, Dennie C, et al: Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res 11:1669-1674, 2005
38. van Ruijven MW, de Groot JC, Hendriksen F, et al: Immunohistochemical detection of platinated DNA in the cochlea of cisplatin-treated guinea pigs. Hear Res 203:112-121, 2005
39. Thomas JP, Lautermann J, Liedert B, et al: High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol Pharmacol 70:23-29, 2006
40. Choi YK, Kim KW: Blood-neural barrier: Its diversity and coordinated cell-to-cell communication. BMB Rep 41:345-352, 2008
41. Neuwelt E, Abbott NJ, Abrey L, et al: Strategies to advance translational research into brain barriers. Lancet Neurol 7:84-96, 2008 (Pubitemid 350258701)
42. Ross CJ, Katzov-Eckert H, Dubé MP, et al: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41:1345-1349, 2009
43. Shord SS, Thompson DM, Krempl GA, et al: Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs 17:207-215, 2006
44. Ekborn A, Laurell G, Andersson A, et al: Cisplatin-induced hearing loss: Influence of the mode of drug administration in the guinea pig. Hear Res 140:38-44, 2000 (Pubitemid 30079633)
45. Brock PR, Koliouskas DE, Barratt TM, et al: Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118:531-534, 1991
46. Riedemann L, Lanvers C, Deuster D, et al: Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 8:23-28, 2008
47. Peters U, Preisler-Adams S, Hebeisen A, et al: Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 11:639-643, 2000
48. Martin LP, Hamilton TC, Schilder RJ: Platinum resistance: The role of DNA repair pathways. Clin Cancer Res 14:1291-1295, 2008 (Pubitemid 351413906)
49. Zhou W, Gurubhagavatula S, Liu G, et al: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced nonsmall cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10: 4939-4943, 2004 (Pubitemid 39099767)
50. Suk R, Gurubhagavatula S, Park S, et al: Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 11:1534-1538, 2005 (Pubitemid 40315237)
51. Prezant TR, Agapian JV, Bohlman MC, et al: Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 4:289-294, 1993 (Pubitemid 23205179)
52. Torroni A, Cruciani F, Rengo C, et al: The A1555G mutation in the 12S rRNA gene of human mtDNA: Recurrent origins and founder events in families affected by sensorineural deafness. Am J Hum Genet 65:1349-1358, 1999 (Pubitemid 30460385)
53. Casano RA, Johnson DF, Bykhovskaya Y, et al: Inherited susceptibility to aminoglycoside ototoxicity: Genetic heterogeneity and clinical implications. Am J Otolaryngol 20:151-156, 1999 (Pubitemid 29196560)
54. Caronia D, Patiño-García A, Milne RL, et al: Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 9:347-353, 2009
55. Oldenburg J, Kraggerud SM, Cvancarova M, et al: Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25:708-714, 2007 (Pubitemid 350002927)
56. Impicciatore M: Pharmacogenomic can give children safer medicines. Arch Dis Child 88:366, 2003
57. NCI-NHGRI Working Group on Replication in Association Studies, Chanock SJ, Manolio T, et al: Replicating genotype-phenotype associations. Nature 447:655-660, 2007
58. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119-137, 2006 (Pubitemid 43261982)
59. Davis JM, Elfenbein J, Schum R, et al: Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. J Speech Hear Disord 51:53-62, 1986 (Pubitemid 16165644)
60. Bess FH, Dodd-Murphy J, Parker RA: Children with minimal sensorineural hearing loss: Prevalence, educational performance, and functional status. Ear Hear 19:339-354, 1998 (Pubitemid 28465218)
61. Horwitz AR, Dubno JR, Ahlstrom JB: Recognition of low-pass-filtered consonants in noise with normal and impaired high-frequency hearing. J Acoust Soc Am 111:409-416, 2002 (Pubitemid 34093335)
62. Stelmachowicz PG, Pittman AL, Hoover BM, et al: The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 130:556-562, 2004 (Pubitemid 38609664)
63. Gurney JG, Tersak JM, Ness KK, et al: Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children's Oncology Group. Pediatrics 120: e1229-e1236, 2007 (Pubitemid 350085519)
64. Neuwelt EA, Brock P: Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 28:1630-1632, 2010
65. Boothroyd A: Developmental factors in speech recognition. Int J Audiol 9:30-38, 1970
66. Beattie RC, Barr T, Roup C: Normal and hearing-impaired word recognition scores for monosyllabic words in quiet and noise. Br J Audiol 31:153-164, 1997 (Pubitemid 27367648)
67. Crandell CC: Speech recognition in noise by children with minimal degrees of sensorineural hearing loss. Ear Hear 14:210-216, 1993
68. Finitzo-Hieber T, Tillman TW: Room acoustics effects on monosyllabic word discrimination ability for normal and hearing-impaired children. J Speech Hear Res 21:440-458, 1978 (Pubitemid 9028171)
69. Gallegos-Castorena S, Martínez-Avalos A, Mohar-Betancourt A, et al: Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol 24:403-408, 2007 (Pubitemid 47301148)
70. Fisher MJ, Lange BJ, Needle MN, et al: Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer 43:780-784, 2004 (Pubitemid 39557716)
71. Fouladi M, Chintagumpala M, Ashley D, et al: Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 26:3749-3755, 2008
72. Lewis MJ, DuBois SG, Fligor B, et al: Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 52:387-391, 2009
73. Chang KW, Chinosornvatana N: Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 28:1788-1795, 2010
74. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422, 1999 (Pubitemid 29022420)
75. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584, 2007
76. Feghali JG, Liu W, Van De Water TR: L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 111:1147-1155, 2001 (Pubitemid 32625400)
77. Choe WT, Chinosornvatana N, Chang KW: Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 25:910-915, 2004 (Pubitemid 39491671)
78. Dickey DT, Muldoon LL, Doolittle ND, et al: Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemother Pharmacol 62:235-241, 2008 (Pubitemid 351692079)
79. Fetoni AR, Sergi B, Ferraresi A, et al: Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity. Acta Otolaryngol 124: 421-426, 2004 (Pubitemid 38797598)
80. Kalkanis JG, Whitworth C, Rybak LP: Vitamin E reduces cisplatin ototoxicity. Laryngoscope 114: 538-542, 2004 (Pubitemid 38391921)
81. Rybak LP, Husain K, Whitworth C, et al: Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: Antioxidant defense system. Toxicol Sci 47:195-202, 1999 (Pubitemid 29214827)
82. Rybak LP, Whitworth C, Somani S: Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope 109:1740-1744, 1999 (Pubitemid 29533912)
83. Mukherjea D, Jajoo S, Whitworth C, et al: Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. J Neurosci 28:13056-13065, 2008
84. Kaltenbach JA, Church MW, Blakley BW, et al: Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg 117:493-500, 1997 (Pubitemid 27508141)
85. Wang J, Lloyd Faulconbridge RV, Fetoni A, et al: Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology 45:380-393, 2003 (Pubitemid 36836134)
86. Church MW, Kaltenbach JA, Blakley BW, et al: The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res 86:195-203, 1995
87. Muldoon LL, Pagel MA, Kroll RA, et al: Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 6:309-315, 2000 (Pubitemid 30065007)
88. Li G, Sha SH, Zotova E, et al: Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 82:585-596, 2002 (Pubitemid 34522371)
89. Lynch ED, Gu R, Pierce C, et al: Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 201:81-89, 2005 (Pubitemid 40255547)
90. Campbell KC, Rybak LP, Meech RP, et al: D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res 102:90-98, 1996 (Pubitemid 26388984)
91. Hussain AE, Blakley BW, Nicolas M, et al: Assessment of the protective effects of amifostine against cisplatin-induced toxicity. J Otolaryngol 32: 294-297, 2003 (Pubitemid 38175959)
92. Hill GW, Morest DK, Parham K: Cisplatin-induced ototoxicity: Effect of intratympanic dexamethasone injections. Otol Neurotol 29:1005-1011, 2008
93. Poirrier AL, Van den Ackerveken P, Kim TS, et al: Ototoxic drugs: Difference in sensitivity between mice and guinea pigs. Toxicol Lett 193:41-49, 2010
94. Blakley BW, Hochman J, Wellman M, et al: Differences in ototoxicity across species. J Otolaryngol Head Neck Surg 37:700-703, 2008
95. Paksoy M, Ayduran E, Sanli A, et al: The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. Med Oncol 28:615-621, 2011
96. Wimmer C, Mees K, Stumpf P, et al: Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol 25:33-40, 2004 (Pubitemid 39077568)
97. More SS, Akil O, Ianculescu AG, et al: Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 30:9500-9509, 2010
98. Korver KD, Rybak LP, Whitworth C, et al: Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 126:683-689, 2002 (Pubitemid 41115249)
99. Campbell KC, Meech RP, Klemens JJ, et al: Prevention of noise- and drug-induced hearing loss with D-methionine. Hear Res 226:92-103, 2007 (Pubitemid 46428036)
100. Harned TM, Kalous O, Neuwelt A, et al: Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin Cancer Res 14:533-540, 2008 (Pubitemid 351226123)
101. Neuwelt EA, Pagel MA, Kraemer DF, et al: Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 309:594-599, 2004 (Pubitemid 38542612)
102. Katzenstein HM, Chang KW, Krailo M, et al: Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: A report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer 115:5828-5835, 2009
103. National Cancer Institute's List of Cancer Clinical Trials. http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=7215792
104. Zuur CL, Simis YJ, Lansdaal PE, et al: Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 25:3759-3765, 2007 (Pubitemid 47372618)
105. Hensley ML, Hagerty KL, Kewalramani T, et al: American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 27: 127-145, 2009
106. Cloven NG, Re A, McHale MT, et al: Evaluation of D-methionine as a cytoprotectant in cisplatin treatment of an animal model for ovarian cancer. Anticancer Res 20:4205-4209, 2000 (Pubitemid 32141765)
107. Campbell K, Nayar R, Borgonha S, et al: Oral D-methionine significantly protects against cisplatin induced hearing loss in humans. Abstracts of the 32nd Annual Midwinter Research Meeting of the Association for Research in Otolarynogology 32:7, 2009 (abstr 22)
108. Lynch ED, Gu R, Pierce C, et al: Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anticancer Drugs 16:569-579, 2005 (Pubitemid 40685742)
109. Lesaffre E: Superiority, equivalence, and non-inferiority trials. Bull NYU Hosp Jt Dis 66:150-154, 2008
110. Li Y, Womer RB, Silber JH: Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer 40:2445-2451, 2004 (Pubitemid 39424959)
111. Chang KW: Clinically accurate assessment and grading of ototoxicity. Laryngoscope 121:2649-2657, 2011